Records containing: Lung Diseases, Interstitial
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-13Early Cancer Detection in Firefighters With Low-Dose Chest CT: A Community-Based Approach
-
CLINICAL_TRIALS study record update · 2026-04-02Video-assisted Thoracic Surgery for Lung Biopsy Using Non-intubated (NIVATS) Versus Intubated General Anaesthesia (IGAVATS): a Randomized, Controlled, Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases
-
CLINICAL_TRIALS study record update · 2026-03-31A Prospective, Observational Study on the Correlations Between Change in Lung Function and Change in Cough and Dyspnoea in Patients With Connective Tissue Disease-associated Progressive Fibrosing INTErstitial luNg diseaSE (CTD Associated PF-ILD) Treated With Nintedanib. The "INTENSE" Study
-
CLINICAL_TRIALS study record update · 2026-03-17Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
-
CLINICAL_TRIALS study record update · 2026-03-16An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-03-04An Open-label Trial of the Long-term Safety and Tolerability of Nintedanib Per os, on Top of Standard of Care, Over at Least 3 Years, in Children and Adolescents With Clinically Significant Fibrosing Interstitial Lung Disease (InPedILD®-ON)
-
CLINICAL_TRIALS study record update · 2026-03-03A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)
-
CLINICAL_TRIALS study record update · 2026-02-27Phase IIa Investigation of H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
-
CLINICAL_TRIALS study record update · 2026-02-06Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
-
CLINICAL_TRIALS study record update · 2026-01-29A Phase 1, Study of Nebulized Matrix - Allogeneic Human Amniotic Fluid (HAF) In Patients With Interstitial Lung Disease: AIRMID Trial
-
CLINICAL_TRIALS study record update · 2026-01-15Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease
-
CLINICAL_TRIALS study record update · 2026-01-13Genetics of Lung Disease (Exhaled Breath DNA Methylation in Lung Carcinogenesis)
-
CLINICAL_TRIALS study record update · 2026-01-09A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
-
CLINICAL_TRIALS study record update · 2025-12-10Exercise Performance on Ambient Air vs. Commonly Prescribed Nasal Low Oxygen Therapy - a Non-Inferiority Trial in Patients With Exercise Induced Desaturation Due to Chronic Lung Diseases
-
CLINICAL_TRIALS study record update · 2025-11-12A Prospective, Multi-national, Cross-sectional Study on a Risk-factor Guided Approach to Interstitial Lung Disease Screening in Patients With Rheumatoid Arthritis at Higher Risk for ILD Using High Resolution Computed Tomography
-
CLINICAL_TRIALS study record update · 2025-10-29Dorothy P. and Richard P Simmons Center for Interstitial Lung Disease Research Registry
-
CLINICAL_TRIALS study record update · 2025-10-28Prospective Observational Investigation of Possible Correlations Between Change in FVC and Change in Cough or Dyspnea Scores Using the Living With Pulmonary Fibrosis Questionnaire (L-PF) Between Baseline and After Approximately 52 Weeks of Nintedanib Treatment in Patients Suffering From Chronic Fibrosing ILD With a Progressive Phenotype
-
CLINICAL_TRIALS study record update · 2025-08-05Longitudinal Study Without an Investigational Medicinal Product in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to Evaluate Novel Imaging-based Biomarkers in Comparison With Lung Function for Use in Early Clinical Development
-
CLINICAL_TRIALS study record update · 2025-07-29Identification of Novel Markers of Human Lung Disease
-
CLINICAL_TRIALS study record update · 2025-06-24Ambispective, Non-Interventional Study to Evaluate the Epidemiology of Interstitial Lung Diseases (ILDs) Associated to Rheumatic Diseases (Rheumatoid Arthritis, Connective Tissue Diseases, Spondylarthritis and Sarcoidosis) and the Progression Risk Factors in the Mexican Population
-
CLINICAL_TRIALS study record update · 2025-06-03Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
-
CLINICAL_TRIALS study record update · 2025-05-20A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Chinese Patients With Chronic Fibrosing ILDs With a Progressive Phenotype
-
CLINICAL_TRIALS study record update · 2025-05-01Comparison of Pulmonary Rehabilitation Efficiency in Home-based With Hospital-based Pulmonary Rehabilitation in Bronchiectasis
-
CLINICAL_TRIALS study record update · 2025-04-25Prospective Observational Investigation of Possible Correlations Between Change in FVC and Change in Cough or Dyspnea Scores Using the Living With Pulmonary Fibrosis Questionnaire (L-PF) Between Baseline and After Approximately 52 Weeks of Nintedanib Treatment in Patients Suffering From Chronic Fibrosing ILD With a Progressive Phenotype
-
CLINICAL_TRIALS study record update · 2025-04-25British Pigeon Fanciers Genetics of Interstitial Lung Disease Study